Effects of P-Selectin Antagonist Inclacumab in Patients Undergoing Coronary Artery Bypass Graft Surgery: SELECT-CABG Trial

J Am Coll Cardiol. 2016 Jan 26;67(3):344-6. doi: 10.1016/j.jacc.2015.10.071.
No abstract available

Publication types

  • Letter
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Coronary Syndrome* / diagnosis
  • Acute Coronary Syndrome* / drug therapy
  • Acute Coronary Syndrome* / etiology
  • Aged
  • Antibodies, Monoclonal* / administration & dosage
  • Antibodies, Monoclonal* / adverse effects
  • Cardiovascular Agents / administration & dosage
  • Cardiovascular Agents / adverse effects
  • Coronary Angiography / methods
  • Coronary Artery Bypass / adverse effects*
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Middle Aged
  • P-Selectin / antagonists & inhibitors*
  • Postoperative Complications* / diagnosis
  • Postoperative Complications* / drug therapy
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Cardiovascular Agents
  • P-Selectin
  • inclacumab

Associated data

  • ClinicalTrials.gov/NCT01245634